Mufg Securities Americas Inc. Boosts Stock Holdings in Cencora, Inc. $COR

Mufg Securities Americas Inc. boosted its position in Cencora, Inc. (NYSE:COR) by 36.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,229 shares of the company’s stock after buying an additional 1,406 shares during the quarter. Mufg Securities Americas Inc.’s holdings in Cencora were worth $1,634,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Cencora by 13.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock worth $15,086,000 after purchasing an additional 5,543 shares during the period. Acadian Asset Management LLC raised its position in shares of Cencora by 947.5% in the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after purchasing an additional 232,539 shares during the period. Mediolanum International Funds Ltd lifted its stake in shares of Cencora by 133.0% during the 3rd quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after buying an additional 32,138 shares in the last quarter. Rhumbline Advisers boosted its holdings in Cencora by 4.0% in the 3rd quarter. Rhumbline Advisers now owns 430,150 shares of the company’s stock worth $134,435,000 after buying an additional 16,539 shares during the period. Finally, Advisors Asset Management Inc. grew its stake in Cencora by 40.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock valued at $5,407,000 after buying an additional 4,973 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,220 shares of company stock valued at $5,282,867 over the last 90 days. Insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Bank of America dropped their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Robert W. Baird set a $415.00 price objective on Cencora in a report on Tuesday, January 13th. Mizuho raised their target price on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. lifted their target price on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus price target of $399.00.

Cencora Price Performance

NYSE:COR opened at $364.80 on Wednesday. Cencora, Inc. has a 52-week low of $244.97 and a 52-week high of $377.54. The stock has a fifty day moving average of $350.19 and a 200 day moving average of $332.57. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm has a market capitalization of $70.96 billion, a price-to-earnings ratio of 43.85, a P/E/G ratio of 1.71 and a beta of 0.68.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.73 EPS. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.